|Articles|June 22, 2017

PAREXEL is Acquired by Pamplona Capital Management

PAREXEL International Corporation announced that Pamplona Capital Management, LLP has acquired all of its outstanding shares, including Parexel's net debt, for $88.10 per share in cash-valued at approximately $5 billion.

Read the full release here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Trending on Applied Clinical Trials Online

PAREXEL is Acquired by Pamplona Capital Management

Related Content

Real-World Evidence in Transition: CRO Adaptation to the European Health Data Space Framework

Why Coordination Failures Get Blamed on Vendors When the Problem Started Much Earlier

ACT Brief: Sponsor Oversight Capability Gaps, Community-Embedded Trial Partnerships, and Trialblazer Timeline Realism

Two New Partnerships Aim to Expand Patient Access to Clinical Trials Through Community-Based Research

Where Capability Gaps Hide When Scientific Intent Doesn't Translate Into Operations

Trending on Applied Clinical Trials Online

Two New Partnerships Aim to Expand Patient Access to Clinical Trials Through Community-Based Research

ACT Brief: Sponsor Oversight Capability Gaps, Community-Embedded Trial Partnerships, and Trialblazer Timeline Realism

Real-World Evidence in Transition: CRO Adaptation to the European Health Data Space Framework

ACT Brief: Product Development Assumptions, Portfolio-Level Recruitment Infrastructure, and Risk-Based Quality Integration

ACT Brief: Portfolio-Level Recruitment Strategy, Structural Change Through Systems Thinking, and Kidney Function Preservation in IgAN